According to the report, studies show that Ozempics active ingredient, semaglutide, increases insulin secretion, lowering blood sugar
The SELECT trial is a major breakthrough, says Yale Medicine cardiologist Harlan Krumholz, MD, SM, explaining that while semaglutide [given as Ozempic] was already known to lower the risk of heart disease in people with diabetes, the SELECT trial was the first to show that Wegovy, which contains a higher dose of semaglutide, also lowers that risk even in people who dont have diabetes
Ania MJ, Louis JA, Nadia NA, Sean W, Lisa C, Breno A, et al
In GLP-1R mRNA relative expression and western blot analysis relative protein expression, the test of significance between the groups was carried out using a non-parametric KruskalWallis test
And so it is very challenging
10.5772/intechopen.94572 30 Gonzalez-RodriguezP